Sermorelin: The Classic GHRH Peptide — Protocol and Evidence

What Sermorelin actually is

Sermorelin is the oldest, best-studied, and most quietly useful peptide in the growth hormone (GH) conversation. It is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH), the natural signal your hypothalamus sends to the pituitary to release GH. Those 29 residues are the biologically active portion of the full 44-amino-acid native hormone, which is why the molecule is sometimes labeled GHRH (1-29) in the literature.

Like other growth hormone secretagogue peptides, Sermorelin does not contain or replace growth hormone itself. It prompts your own pituitary gland to release the GH it is already capable of producing. That distinction sounds technical, but it is the entire clinical case for choosing a GHRH analog over exogenous recombinant human growth hormone (rhGH): the pituitary remains in the loop, the feedback system stays intact, and GH continues to be released in the pulsatile pattern the body evolved to use.

What sets Sermorelin apart from newer GHRH analogs is its history. It was developed in the 1970s and 1980s, FDA-approved in 1997 for pediatric growth hormone deficiency, and later withdrawn from the U.S. market in 2008 for commercial reasons unrelated to safety or efficacy. It returned through the compounding pharmacy route and has remained the workhorse GHRH peptide in regenerative and longevity clinics for nearly two decades.

At Regeneris Therapy in Cancún, we treat Sermorelin the way we treat any clinical tool: honestly, narrowly, and within the limits of what the evidence supports.

What the clinical evidence actually shows

The published evidence base for Sermorelin is, by peptide standards, unusually deep. There are decades of pharmacokinetic data, controlled pediatric studies of GH deficiency, adult studies of GH secretion in healthy and aging populations, and a meaningful body of clinical experience from compounding-pharmacy use since 2008.

Pituitary stimulation is well-established. Sermorelin produces a reproducible, dose-dependent GH pulse when administered subcutaneously to adults with intact pituitary function. The pulse peaks at around 15 to 30 minutes and resolves within an hour. That short, clean profile mimics endogenous GHRH signaling rather than overriding it.

IGF-1 elevation is modest and physiologic. Long-term Sermorelin protocols in adults typically produce IGF-1 increases that move from the low end of normal toward the middle or upper-normal range, rather than into supraphysiologic territory. Several anti-aging clinical groups have published open-label series suggesting improvements in body composition, sleep quality, and subjective well-being over 6 to 12 month protocols. The data are real but uneven: most series are open-label, single-center, and small.

Large randomized trials in healthy adults are limited. The strongest Sermorelin data come from pediatric GH deficiency and mechanism-confirming adult studies. Large placebo-controlled trials demonstrating that Sermorelin reverses age-related decline in otherwise healthy adults do not exist in 2026. Anti-aging claims are extrapolated from GH and IGF-1 physiology, supported by clinical experience, but not the same as a validated indication.

The fair summary: Sermorelin sits on a longer evidence track record than newer GHRH analogs, with a well-characterized pharmacology and a long safety profile, but the "anti-aging" framing remains an extrapolation rather than a proven outcome.

For context on how Sermorelin fits among other peptides, our overview of peptide therapy covers the landscape, and our anti-aging program describes how peptides integrate into a broader longevity plan.

Body composition, sleep, and recovery: what to expect

The downstream effects of restoring or amplifying a GH pulse are biologically real and predictable in direction, if not always in magnitude.

Body composition. GH promotes lipolysis and supports lean muscle protein synthesis through IGF-1. In adults on a 6-month Sermorelin protocol, paired with resistance training and adequate protein, modest decreases in visceral fat and modest increases in lean mass are a reasonable expectation. "Modest" is the operative word.

Sleep. Endogenous GH is released primarily during slow-wave sleep in the first hours of the night. Amplifying that pulse with a bedtime Sermorelin dose has been linked in clinical reports to improvements in subjective sleep quality and deep-sleep time. Patients with undiagnosed sleep apnea will not get sleep benefits from any peptide until the apnea is treated.

Recovery. GH and IGF-1 contribute to tissue repair, collagen synthesis, and post-exercise recovery. Many patients report faster recovery from training and better workout tolerance on Sermorelin. Controlled data in healthy adults are limited, but the physiologic rationale is sound.

What Sermorelin will not do: replace sleep, replace training, fix metabolic dysfunction caused by diet, or produce the kind of dramatic transformation that is sometimes marketed in less honest corners of the longevity space.

Sermorelin vs CJC-1295: how they differ

The comparison patients ask about most often is Sermorelin versus the newer GHRH analogs, particularly CJC-1295. Both are GHRH-based, both stimulate pituitary GH release, and both are commonly used in regenerative settings. The differences are clinically meaningful.

Half-life and dosing rhythm. Sermorelin has a very short half-life of roughly 10 to 20 minutes, requiring nightly dosing. CJC-1295 exists in two forms: Modified GRF (1-29), with a half-life around 30 minutes; and CJC-1295 with DAC, which binds plasma albumin and produces sustained elevation over 6 to 8 days, dosed weekly.

Pulsatility. Sermorelin and Modified GRF (1-29) both preserve the body's natural pulsatile GH rhythm. CJC-1295 with DAC overrides it. For clinicians who prioritize physiology over convenience, the short-acting GHRH analogs are usually the preferred starting point.

Evidence base. Sermorelin has decades of published data, prior FDA approval, and a long clinical track record. CJC-1295, particularly the DAC form, has well-designed pharmacokinetic studies but a shorter clinical history and less long-term outcome data.

Combination with Ipamorelin. Both are routinely stacked with Ipamorelin to amplify the GH pulse through two complementary receptors. We discuss the CJC-1295 version in detail in our companion piece on CJC-1295 + Ipamorelin.

In short: Sermorelin is the older, better-studied, shorter-acting GHRH analog. CJC-1295 is the newer, more aggressively marketed alternative with a longer-acting variant. For most patients starting a GH secretagogue protocol, Sermorelin remains the reasonable first choice.

Typical dosing and protocol structure

Specific dosing belongs in a physician's office, not in a blog post. The general structure of a Sermorelin protocol Mexico clinics commonly use, presented as illustrative rather than prescriptive:

• Route. Subcutaneous injection, rotating between abdomen and thigh sites. Compounding pharmacies typically dispense Sermorelin as a lyophilized powder that is reconstituted with bacteriostatic water.
• Timing. Bedtime, on an empty stomach. A meal, particularly one containing carbohydrates or fat, blunts the GH response. Endogenous GH pulses occur during early deep sleep, and bedtime dosing aligns the peptide pulse with the body's natural rhythm.
• Dose range. Published clinical and compounding-pharmacy protocols commonly use Sermorelin in the range of 100 to 500 micrograms per nightly dose, often combined with Ipamorelin in the 100 to 300 microgram range. Individual titration is the norm.
• Cycle structure. Most clinicians use cyclical dosing, typically 5 nights on and 2 nights off, in 3 to 6 month cycles followed by a washout, to preserve pituitary responsiveness and avoid receptor desensitization.
• Monitoring. Baseline and follow-up labs typically include IGF-1, fasting glucose, HbA1c, lipid panel, thyroid function, and (depending on clinical context) a morning cortisol. IGF-1 is the most useful surrogate for whether the protocol is producing a biological effect and whether it is staying within a physiologic range.

What no responsible protocol looks like: flat dosing for everyone, no labs, no follow-up, no contraindication screening, and no conversation about expectations. If that is what is being offered, it is not clinical peptide therapy.

Contraindications and who should not take this

GH-axis interventions touch many systems, which is why Sermorelin requires careful screening before prescription. The categories where it is contraindicated or requires special caution include:

• Active or recent malignancy. Elevated IGF-1 has been associated with growth of certain tumor types. Active cancer, recent cancer treatment, or strong personal or family history requires careful oncology input before any GH-axis intervention.
• Pregnancy and breastfeeding. No safety data exist; not appropriate.
• Pediatric and adolescent patients outside specialist care. Children with diagnosed GH deficiency are managed by pediatric endocrinology with FDA-approved rhGH, not by regenerative clinics with secretagogue peptides.
• Diabetes and impaired glucose tolerance. GH is counter-regulatory to insulin. Patients with type 2 diabetes, pre-diabetes, or impaired fasting glucose require careful endocrine assessment, and many are not appropriate candidates.
• Active diabetic retinopathy. GH and IGF-1 elevation can worsen proliferative retinopathy.
• Untreated severe sleep apnea, untreated thyroid disease, or known pituitary pathology. Each requires evaluation and stabilization before any GH-axis manipulation.

Side effects in appropriate candidates are typically mild and dose-dependent: transient injection-site reactions, occasional flushing or lightheadedness shortly after dosing, vivid dreams, and mild water retention. Persistent paresthesias, joint discomfort, or rising fasting glucose are reasons to reduce the dose or stop, and the reason monitoring labs exist.

COFEPRIS regulation and the Cancún context

In Mexico, peptide therapy operates under a specific regulatory framework that any patient should understand before agreeing to a protocol. The Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) regulates pharmaceutical substances and the clinical environments in which they are administered.

As of 2026, Sermorelin is not a COFEPRIS-registered finished pharmaceutical product with an approved adult anti-aging indication. It is accessed through licensed compounding pharmacies operating under the *farmacia magistral* framework, the same framework that governs custom-formulated medications across many therapeutic categories.

In practice, any patient considering Sermorelin in Cancún should expect three things:

• A written prescription from a licensed Mexican physician after an in-person evaluation, including baseline labs. Online direct-to-consumer sales of Sermorelin as a "research chemical" sit outside the standard of care.
• Source documentation. A reputable compounding pharmacy provides Certificates of Analysis for each lot, documenting peptide identity, purity, and absence of endotoxin. Your clinic should be able to show these for the specific lot dispensed.
• A notified clinical setting. Administration, training in self-injection, and follow-up should take place within a COFEPRIS-notified clinical environment with documented informed consent.

For international patients traveling to Cancún for medical tourism, a Sermorelin protocol is not a one-visit transaction. The first visit is evaluation and baseline labs; subsequent care includes training in self-administration, a defined cycle length, and follow-up labs at appropriate intervals.

Who is a reasonable candidate

There is no universal candidate for GH secretagogue peptides, and there is no version of this conversation where the answer is "everyone over forty." Based on current evidence and our clinical experience, the patients most likely to be appropriate for Sermorelin are:

• Adults in their late thirties through sixties with documented age-related decline in GH and IGF-1, a clinical picture that includes reduced recovery capacity, deteriorating sleep, and body composition changes that have not responded to first-line lifestyle interventions.
• Patients who want a GHRH analog with the longest published track record and a short-acting, pulse-preserving profile, rather than a longer-acting or newer alternative.
• Athletes and active adults in structured training and recovery programs who have already optimized training load, sleep hygiene, and nutrition, and for whom a supervised Sermorelin cycle is being considered as an adjunct rather than as a primary intervention.
• Patients in supervised longevity protocols who already have baseline labs, an established clinical relationship, and a clear plan for monitoring and discontinuation.

The patients for whom this is not appropriate are equally important to name: anyone seeking a quick fix instead of doing the work, anyone whose primary issue is undiagnosed sleep apnea or thyroid dysfunction, anyone with the contraindications listed above, and anyone whose expectations have been set by social media rather than by a physician.

Moving forward with clarity

Sermorelin is the classic GHRH peptide for a reason. It has a longer published track record than its successors, a short half-life that preserves natural GH pulsatility, a well-characterized safety profile, and decades of clinical use. Within a supervised plan, in a properly selected patient, paired with the boring fundamentals of training, sleep, and nutrition, it is a reasonable tool in the regenerative medicine and longevity conversation. Without those fundamentals, no peptide will deliver what its marketing promises.

If you are considering Sermorelin or another peptide therapy in Cancún, the right first step is a physician evaluation with appropriate labs, not a product order from an online vendor. You can learn more about our peptide therapy program and our anti-aging and longevity approach, or contact our medical team to discuss whether this protocol is appropriate for your specific clinical picture.

Related reading

• CJC-1295 + Ipamorelin: Protocol and Evidence
• BPC-157 in Mexico: What We Know as of 2026
• Anti-Aging and Longevity in Regenerative Medicine